

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Dox 1450 Alexandra, Viginia 22313-1450

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/666,998

09/19/2003

Andrei Laikhter

PA2003-4

34916 INTEGRATED DNA TECHNOLOGIES, INC. 8930 GROSS POINT RD. SUITE 700 SKOKIE, IL 60077



CONFIRMATION NO. 1003 FORMALITIES LETTER *OC000000011606574*

Date Mailed: 01/02/2004

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Filing Date Granted

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help. call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to:

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

A copy of this notice <u>MUST</u> be returned with the reply.

Y.6

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

DIPE VOLUME

DT20 Rec'd PTPTO 12 JAN 2004

pet

2 2004 2		DTO/SD/94 (00 00)
رخ	116.1	PTO/SB/21 (08-03) Approved for use through 08/30/2003. OMB 0651-0031 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995. no	persons are required to respond to a co	lection of information unless it displays a valid OMB control number.
BELLE CONTROL OF THE PARTY OF T	Application Number	10/666998
TRANSMITTAL	Filing Date	September 19, 2003
FORM	First Named Inventor	Andrei Laikhter
(to be used for all correspondence after initial fili	ng) Art Unit	1743
· ·	Examiner Name	unknown
Total Number of Pages in This Submission 4	Attorney Docket Number	PA2003-4
ENCLOSURES (Check all that apply)		
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence of Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name Robert Gould Vice President of Intellectua Integrated DNA Technologie Signature January 6, 2004	es, Inc.	
CEI	RTIFICATE OF TRANSMISS	ION/MAILING
I hereby certify that this correspondence is being sufficient postage as first class mail in an enverthe date shown below.	ng facsimile transmitted to the USPT lope addressed to: Commissioner fo	O or deposited with the United States Postal Service with r Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on
Typed or printed name Robert	-bould	
Signature Kulis	thould	Date 1/6/2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this

- Transmittal Form,
- Response to Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures,
- copy of Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, and
- postcard

(along with any documents referred to as being attached or enclosed) are being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Missing Parts Commissioner for Patents, PO Box 1450 Alexandria, VA 22313-1450

Date: January 6, 2004

Robert Gould



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Laikhter et al.

Art Unit: 1743

Application No.

10/666,998

Examiner: unknown

Filed:

09/19/2003

For:

Anthraquinone quencher dyes, their methods of preparation

and use

Response to Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures

Mail Stop Missing Parts Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence Disclosures the Applicant submits the following statement:

Pursuant to 37 C.F.R. § 1.821 the undersigned states that the sequence listing information recorded in computer readable form filed with the application on September 19, 2003 is identical to the written sequence listing filed with the application on September 19, 2003.

A copy of the Notice is enclosed with this reply.

January 6, 2004

Robert M. Gould

Registration No.: 43,642

Vice President of Intellectual Property Integrated DNA Technologies, Inc.

Customer No. 34,916